Genmab A/S (NASDAQ:GMAB) Price Target Raised to $40.00 at HC Wainwright

Genmab A/S (NASDAQ:GMAB) had its target price raised by equities research analysts at HC Wainwright from $39.00 to $40.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 33.33% from the stock’s current price.

A number of other equities research analysts have also recently commented on the stock. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Morgan Stanley started coverage on shares of Genmab A/S in a research note on Monday. They set an “equal weight” rating and a $34.00 price objective for the company. Jefferies Financial Group started coverage on shares of Genmab A/S in a research note on Tuesday. They issued a “buy” rating and a $41.50 target price on the stock. Wall Street Zen cut Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Finally, Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.30.

Genmab A/S Stock Performance

Shares of GMAB opened at $30.00 on Wednesday. The stock has a 50 day moving average price of $32.30 and a 200 day moving average price of $29.88. Genmab A/S has a one year low of $17.24 and a one year high of $35.43. The stock has a market capitalization of $19.27 billion, a price-to-earnings ratio of 12.77, a PEG ratio of 17.63 and a beta of 0.90.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Founders Capital Management lifted its stake in shares of Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares during the last quarter. Parallel Advisors LLC boosted its stake in Genmab A/S by 11.3% during the third quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock worth $127,000 after buying an additional 419 shares during the period. CWM LLC increased its position in shares of Genmab A/S by 18.8% during the fourth quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after acquiring an additional 433 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Genmab A/S by 29.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock worth $57,000 after acquiring an additional 440 shares during the last quarter. Finally, Osaic Holdings Inc. boosted its position in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Key Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Q4 results beat on EPS and showed robust profitability — Genmab reported $0.47 EPS vs. $0.46 consensus and $1.06B revenue (in line), with strong margins and growth commentary that support longer-term revenue momentum. Genmab AS (GMAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions
• Positive Sentiment: Board approved a targeted share buy-back to cover RSU commitments — repurchase of up to 342,130 shares (max ~725 million DKK) should be EPS-accretive and supports shareholder value. Genmab Announces Initiation of Share Buy-Back Program
• Positive Sentiment: Brokerage consensus remains favorable — recent aggregation shows a “Moderate Buy” consensus from brokerages, which can support investor confidence. Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages
• Positive Sentiment: Jefferies initiated coverage with a Buy rating and a $41.50 price target — a material upside signal from a sell-side shop that could attract buyers. Benzinga coverage note
• Neutral Sentiment: Morgan Stanley started coverage with an Equal Weight rating and $34 price target — provides incremental liquidity/coverage but is a neutral, less bullish signal than some peers. Morgan Stanley Begins Coverage on Genmab A/S (NASDAQ:GMAB)
• Neutral Sentiment: Genmab published and filed its 2025 annual report / Form 20-F — useful for fundamentals and guidance detail but not a near-term price mover by itself. Genmab Files Annual Report with the U.S. Securities and Exchange Commission Genmab Publishes 2025 Annual Report
• Neutral Sentiment: FY‑2026 guidance entry in the feed appears garbled/unreliable (reported revenue ranges and EPS text are inconsistent). Investors should rely on company releases/slides for authoritative guidance rather than the malformed bulletin.
• Neutral Sentiment: Short-interest data in the feed is inconsistent/empty — no clear signal from short activity.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.